Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.42)
# 993
Out of 4,987 analysts
208
Total ratings
50.81%
Success rate
3.06%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Overweight | $215 → $245 | $222.47 | +10.13% | 16 | Sep 15, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $975 → $825 | $751.99 | +9.71% | 13 | Aug 13, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $485 | $383.12 | +26.59% | 4 | Aug 5, 2025 | |
| AMGN Amgen | Reiterates: Neutral | $305 | $285.41 | +6.86% | 17 | Jun 24, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $55 | $45.02 | +22.17% | 16 | Apr 23, 2025 | |
| REGN Regeneron Pharmaceuticals | Assumes: Overweight | $695 | $591.99 | +17.40% | 20 | Apr 22, 2025 | |
| PFE Pfizer | Initiates: Neutral | $24 | $24.03 | -0.12% | 15 | Apr 22, 2025 | |
| PCVX Vaxcyte | Initiates: Overweight | n/a | $31.75 | - | 1 | Apr 22, 2025 | |
| MRK Merck & Co. | Initiates: Neutral | $85 | $81.51 | +4.28% | 11 | Apr 22, 2025 | |
| GILD Gilead Sciences | Assumes: Overweight | $125 | $114.09 | +9.56% | 15 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $145.23 | +13.61% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $24.85 | -19.52% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $142.50 | +26.32% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $100 | $76.67 | +30.43% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $60 | $27.24 | +120.26% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $1.08 | +177.47% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.32 | +581.82% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $48.66 | +95.23% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $14.30 | +39.86% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $77.86 | -6.24% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $3.03 | +296.04% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $3.05 | -50.82% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $0.43 | +417.60% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $216.60 | +75.44% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $86.53 | -5.24% | 5 | Jan 16, 2019 |
AbbVie
Sep 15, 2025
Maintains: Overweight
Price Target: $215 → $245
Current: $222.47
Upside: +10.13%
Eli Lilly and Company
Aug 13, 2025
Maintains: Overweight
Price Target: $975 → $825
Current: $751.99
Upside: +9.71%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Overweight
Price Target: $535 → $485
Current: $383.12
Upside: +26.59%
Amgen
Jun 24, 2025
Reiterates: Neutral
Price Target: $305
Current: $285.41
Upside: +6.86%
Bristol-Myers Squibb Company
Apr 23, 2025
Reiterates: Neutral
Price Target: $55
Current: $45.02
Upside: +22.17%
Regeneron Pharmaceuticals
Apr 22, 2025
Assumes: Overweight
Price Target: $695
Current: $591.99
Upside: +17.40%
Pfizer
Apr 22, 2025
Initiates: Neutral
Price Target: $24
Current: $24.03
Upside: -0.12%
Vaxcyte
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $31.75
Upside: -
Merck & Co.
Apr 22, 2025
Initiates: Neutral
Price Target: $85
Current: $81.51
Upside: +4.28%
Gilead Sciences
Apr 22, 2025
Assumes: Overweight
Price Target: $125
Current: $114.09
Upside: +9.56%
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $145.23
Upside: +13.61%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $24.85
Upside: -19.52%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $142.50
Upside: +26.32%
Aug 29, 2024
Initiates: Overweight
Price Target: $100
Current: $76.67
Upside: +30.43%
Aug 14, 2024
Maintains: Overweight
Price Target: $200 → $60
Current: $27.24
Upside: +120.26%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $1.08
Upside: +177.47%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.32
Upside: +581.82%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $48.66
Upside: +95.23%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $14.30
Upside: +39.86%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $77.86
Upside: -6.24%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $3.03
Upside: +296.04%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $3.05
Upside: -50.82%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $0.43
Upside: +417.60%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $216.60
Upside: +75.44%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $86.53
Upside: -5.24%